drTarget portfolio target-disease associations for Infectious diseases

OpenTargets offers > 22k target-disease associations from PChem targets suitable for virtual screening based in OpenTargets scores for infectious diseases. See here the best scored pairs.

Select genes or diseases. Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	HIV-1 infection	targetBased	67275	2509	0.417632019115235	224
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	infection	targetBased	394050	3624	0.587888525022768	255
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	infection	targetBased	325247	1021	0.295001179173854	57
HTS of Smad transcription factor inhibitors	SMAD3	infection	targetBased	88033	251	0.363448158025365	87
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	infection	targetBased	316642	617	0.523915285191001	83
uHTS identification of small molecule modulators of NR3A	GRIN3A	infection	targetBased	339772	8480	0.660276964107463	81
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	infection	pathwayBased	43989	342	0.332381905893642	798
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	infection	targetBased	343468	734	0.412883595696792	774
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	severe acute respiratory syndrome	targetBased	217959	2390	0.364012517510198	6
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	severe acute respiratory syndrome	pathwayBased	193265	3100	0.408633158137904	62
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	severe acute respiratory syndrome	pathwayBased	359244	3094	0.408633158137904	62
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	severe acute respiratory syndrome	targetBased	330392	1295	0.510857776805646	30
HTS of Smad transcription factor inhibitors	SMAD3	severe acute respiratory syndrome	targetBased	88033	251	0.511088225242917	8
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	severe acute respiratory syndrome	targetBased	314998	2199	0.507239609926207	6
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	severe acute respiratory syndrome	targetBased	343468	734	0.433588208983584	20
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	viral disease	targetBased	57013	201	0.533448005700228	76
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	viral disease	targetBased	383363	2142	0.509151952880039	8
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	viral disease	targetBased	318291	483	0.425328012012717	29
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	viral disease	targetBased	343468	734	0.261521416976797	508
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	HIV infection	targetBased	290355	265	0.414922240062954	16
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	HIV infection	targetBased	86095	1442	0.575537830851285	26
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	HIV infection	targetBased	86095	1151	0.575537830851285	26
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	HIV infection	targetBased	143816	859	0.663611509897898	18
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	HIV infection	targetBased	46715	2829	0.408233132436577	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	HIV infection	targetBased	394050	3624	0.409048338790806	45
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	HIV infection	targetBased	335239	991	0.427570622736267	36
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	HIV infection	targetBased	335239	695	0.427570622736267	36
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	99314	335	0.385423106269835	39
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196176	782	0.385423106269835	39
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	99314	390	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196177	811	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196176	670	0.385423106269835	39
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	HIV infection	targetBased	196177	519	0.385423106269835	39
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	HIV infection	targetBased	369953	2353	0.648992922909193	91
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	HIV infection	targetBased	316642	617	0.305911386425869	6
qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G_inhibitors	HIV infection	targetBased	402348	311	0.618941190389532	116
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G_inhibitors	HIV infection	targetBased	331753	931	0.618941190389532	116
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	malaria	targetBased	316642	617	0.509680221819924	11
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	malaria	targetBased	343468	734	0.642740677354967	196
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	urinary tract infection	targetBased	86095	1442	0.598304433739899	28
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	urinary tract infection	targetBased	86095	1151	0.598304433739899	28
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hepatitis C virus infection	targetBased	394050	3624	0.381339684466849	30
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	99314	335	0.544053842545307	19
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196176	782	0.544053842545307	19
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	99314	390	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196177	811	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196176	670	0.544053842545307	19
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatitis C virus infection	targetBased	196177	519	0.544053842545307	19
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	pneumonia	targetBased	217959	2390	0.322273166818187	10
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pneumonia	pathwayBased	362051	17187	0.292812792979543	77
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	pneumonia	targetBased	343468	734	0.374953231195365	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic hepatitis C virus infection	targetBased	394050	3624	0.48907279326285	8
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	99314	335	0.556882803103682	6
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196176	782	0.556882803103682	6
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	99314	390	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196177	811	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196176	670	0.556882803103682	6
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic hepatitis C virus infection	targetBased	196177	519	0.556882803103682	6
uHTS identification of small molecule modulators of NR3A	GRIN3A	chronic hepatitis C virus infection	targetBased	339772	8480	0.536969177145771	8
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	Creutzfeldt Jacob Disease	targetBased	369953	1596	0.794969944120682	206
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic hepatitis B virus infection	targetBased	394050	3624	0.416323703141132	14
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	prion disease	targetBased	369953	1596	0.829860821013757	4242
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Herpes Zoster	targetBased	316642	617	0.286121727579184	6
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	influenza	targetBased	63696	220	0.406110621508939	6
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	influenza	targetBased	290726	2649	0.406110621508939	6
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	influenza	targetBased	217959	2390	0.286421877101544	10
qHTS for Inhibitors of TGF-b	TGFB1	influenza	pathwayBased	403345	4970	0.426507766239587	102
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	influenza	targetBased	394050	3624	0.284185473999202	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	bronchiolitis obliterans	targetBased	339297	1446	0.368678188787264	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	influenza	targetBased	316642	617	0.601285568397495	9
uHTS identification of small molecule modulators of NR3A	GRIN3A	influenza	targetBased	339772	8480	0.660725338872141	104
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	influenza	targetBased	343468	734	0.295920889253573	44
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	listeriosis	targetBased	193542	587	0.593396752228544	8
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	coronavirus infectious disease	targetBased	343468	734	0.419752638612533	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	septic shock	targetBased	335239	991	0.601285568397495	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	septic shock	targetBased	335239	695	0.601285568397495	9
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	septic shock	targetBased	324747	813	0.613407008594561	33
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	septic shock	targetBased	290355	265	0.577168330395272	6
uHTS identification of small molecule modulators of NR3A	GRIN3A	septic shock	targetBased	339772	8480	0.536969177145771	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	septic shock	targetBased	339297	1446	0.638939480030344	42
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	viral pneumonia	targetBased	343468	734	0.318572936377036	8
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	susceptibility to childhood ear infection measurement	targetBased	306502	3633	0.382327220816372	6
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	susceptibility to childhood ear infection measurement	targetBased	335180	1022	0.382327220816372	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	serum lipopolysaccharide activity	targetBased	339297	1446	0.407834936241567	17
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	pulmonary tuberculosis	targetBased	394050	3624	0.39163880691884	104
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Helicobacter pylori infectious disease	targetBased	394050	3624	0.298431454792675	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Recurrent infection of the gastrointestinal tract	targetBased	335239	991	0.595650699705387	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Recurrent infection of the gastrointestinal tract	targetBased	335239	695	0.595650699705387	9
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Sepsis	targetBased	217959	2390	0.294934461313262	71
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Sepsis	targetBased	394050	3624	0.551397408916636	46
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Sepsis	targetBased	324747	813	0.406557917385719	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Sepsis	targetBased	339297	1446	0.6612711090907	66
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Sepsis	targetBased	316642	617	0.316719591125081	56
HCS assay for microtubule stabilizers	TUBB	fungal infectious disease	targetBased	195821	1625	0.507022442086813	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	nasopharyngeal carcinoma	pathwayBased	321427	201	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	54509	528	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	54513	338	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	125394	1890	0.737012287640562	68
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal carcinoma	targetBased	124022	1156	0.737012287640562	68
HCS assay for microtubule stabilizers	TUBB	nasopharyngeal carcinoma	targetBased	195821	1625	0.458606950008097	98
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	tuberculosis	targetBased	394050	3624	0.446708744563635	223
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)	ASAP1_inhibitors	tuberculosis	targetBased	362577	680	0.413430315879523	24
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	respiratory tract infectious disorder	targetBased	75924	1804	0.251958915626748	8
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	respiratory tract infectious disorder	targetBased	316642	617	0.441745739262982	10
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	postherpetic neuralgia	targetBased	316642	617	0.443995984976086	15
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	COVID-19	targetBased	63696	220	0.290490012238163	42
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	COVID-19	targetBased	290726	2649	0.290490012238163	42
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	COVID-19	targetBased	217959	2390	0.455374500916603	189
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	COVID-19	targetBased	359207	1432	0.400618075800315	20
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	COVID-19	targetBased	363840	3086	0.52529188517202	104
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	COVID-19	targetBased	143816	859	0.436786846668777	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	COVID-19	targetBased	363803	2412	0.294971288860141	9
uHTS HTRF assay for identification of inhibitors of SUMOylation	UBE2I	COVID-19	targetBased	290915	1039	0.406922042600603	6
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	COVID-19	targetBased	394050	3624	0.661807962739989	108
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	COVID-19	targetBased	335239	991	0.324128571915494	14
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	COVID-19	targetBased	335239	695	0.324128571915494	14
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	COVID-19	pathwayBased	195980	5134	0.414354084594448	200
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	COVID-19	targetBased	195980	695	0.414354084594448	200
uHTS identification of SUMO1-mediated protein-protein interactions	SUMO1	COVID-19	targetBased	363840	1202	0.409751479216971	9
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	COVID-19	pathwayBased	362051	17187	0.332705533107256	2165
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	COVID-19	targetBased	306502	3633	0.406313476781855	6
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	COVID-19	targetBased	335180	1022	0.406313476781855	6
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	COVID-19	targetBased	330392	1295	0.443727828132228	719
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	COVID-19	targetBased	339297	1446	0.316501490861286	20
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	COVID-19	targetBased	305610	3794	0.52560928186248	6
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	COVID-19	targetBased	339674	2841	0.52662355822706	8
Thrombin 1536 HTS	F2_modulation	COVID-19	targetBased	217233	557	0.412497319279211	612
HCS assay for microtubule stabilizers	TUBB	COVID-19	targetBased	195821	1625	0.570269521289546	42
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	COVID-19	targetBased	316642	617	0.401058368093982	26
uHTS identification of small molecule modulators of NR3A	GRIN3A	COVID-19	targetBased	339772	8480	0.400520831766368	9
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	COVID-19	targetBased	343468	734	0.681978936473465	329
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	central nervous system infection	targetBased	369953	1596	0.320854290764917	2389
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	infectious disorder of the nervous system	targetBased	369953	1596	0.320854290764917	2389
qHTS assay for re-activators of p53 using a Luc reporter	TP53	post-infectious disorder	pathwayBased	321427	201	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	54509	528	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	54513	338	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	125394	1890	0.279352313554424	326
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	post-infectious disorder	targetBased	124022	1156	0.279352313554424	326

Some of these associations have also gone through clinical trials.

graph

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

table